Otsuka Encounters Split Responses For Drug For Rare Kidney Disease
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical won one and lost one half a world apart for its Samsca (tolvaptan) for treating a rare type of kidney disease, rejected in the U.S., accepted at home in Japan.